Late breaking trials & Clinical Trials

Late Breaking Trials

• The Selective Cardiac Myosin Activator, CK-1827452, Increases Systolic Function in Heart Failure -  Principal Investigators : J. Cleland FESC (UK)  J McMurray FESC (UK)
• Pre-RELAX-AHF -  Principal Investigators : JR Teerlink FESC (US) M Metra FESC (IT)
• Congestive Heart failure: A multidisciplinary Non-pharmacological approach for Changing in rE-hospitalisation and  prognosis (CHANCE) - Principal Investigator : Prof V Mareev ( RUS)
• B convinced - Principal Investigator : G Jondeau FESC, Chronic Heart failure Assistance by Telephone (CHAT) - Principal Investigator : H Krum (AU)
• Beta-blocker tolerance in elderly patients with heart failure: The Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD) Trial -  Principal Investigator : HD Duengen
• Exercise training in heart failure with preserved ejection fraction (Ex-DHF) - Principal Investigator:  B Pieske
• SIGNAL-HF - A Randomized Study of NT-proBNP Guided Management of Heart failure in Elderly Primary Care Patients Principal Investigator: H Persson FESC (SE) -  Principal Investigators : J. Cleland FESC (UK)  J McMurray FESC (UK)

Additional trials presentation

 this year , we presented Highlights of the Moderated Poster Sessions  - a perfect opportunity to meet the investigator/presenter

• Randomized controlled trial on the cardioprotective effects of _bone marrow cells in patients undergoing coronary artery bypass graft surgery
• Influence of Myocardial Sympathetic Innervation on Occurrence of Fatal and Non-fatal Arrhythmic Events in Heart Failure Patients: New Insights from the Prospective Multicenter International ADMIRE-HF Trial
• TITAN Trial 
• The burden of asymptomatic left ventricular dysfunction and congestive heart failure in elderly: a population-based study in Italy. The  PREDICTOR Study. 

CLINICAL TRIALS presented at HEART FAILURE 2009 

• ATMOSPHERE A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV)
• ASTRONAUT A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the 6 months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mortality when initiated early after hospitalization for acute decompensated heart failure  A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the 6 months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mortality when initiated early after hospitalization for acute decompensated heart failure
• TRIDENT-1 TReatment with Intravenous BG9928 for patients with acute DEcompensated heart failure and reNal dysfunction Trial  TReatment with Intravenous BG9928 for patients with acute DEcompensated heart failure and reNal dysfunction Trial
• POSEIDON Placebo controlled Oral Study of BG9928 in hEart faIlure patients with renal DysfunctiON  Placebo controlled Oral Study of BG9928 in hEart faIlure patients with renal DysfunctiON
• Echo CRT - Echo guided Cardiac Resynchronisation Therapy
• European CRT Survey European Cardiac Resynchronisation Survey European Cardiac Resynchronisation Survey
• EFFICACY-HF EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac function in patients with iron deficiencY and chronic Heart Failure EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac function in patients with iron deficiencY and chronic Heart Failure
• LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction - A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of
• RED-HF Trial - Reduction of Events with Darbepoetin alfa in Heart Failure Trial
• HEAAL Comparison of Low-Dose Versus High-Dose Losartan Treatment on Morbidity and Mortality in Angiotensin Converting Enzyme-Inhibitor Intolerant Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction: Results of the HEAAL Study
• RELAX-AHF-1 A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure
• SHIFT (Systolic Heart failure treatment with the If inhibitor Ivabradine Trial) Effects of Ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction
• ASCEND-HF Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure - A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV)